Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics (PK) of CC-122 in Subjects With Mild, Moderate and Severe Renal Impairment
Conditions
Interventions
CC-122
Locations
2
United States
DaVita Clinical Research
Lakewood, Colorado, United States
DaVita Clinical Research
Minneapolis, Minnesota, United States
Start Date
March 30, 2017
Primary Completion Date
December 23, 2017
Completion Date
December 23, 2017
Last Updated
April 26, 2018
NCT01524276
NCT07262333
NCT02769975
NCT06314503
NCT06659835
NCT06863194
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions